Biogen and AbbVie Announce the Voluntary Worldwide Withdrawal of Marketing Authorizations for ZINBRYTA® (daclizumab) for Relapsing Multiple Sclerosis

More Evidence of Link Between Severe Gum Disease and Cancer Risk
March 2, 2018
Cancer, the Flu, and You
March 5, 2018
Show all

Biogen and AbbVie Announce the Voluntary Worldwide Withdrawal of Marketing Authorizations for ZINBRYTA® (daclizumab) for Relapsing Multiple Sclerosis

Comments are closed.